Treatment of patients with knee osteoarthritis with hyaluronate sodium (Revisk) in clinical practice

Abstract

BACKGROUND: Osteoarthritis is a disease highly associated with a wide range of comorbidities, which leads to significant limitations of the therapeutic possibilities, in particular, the long-term use of non-steroidal anti-inflammatory drugs. Thus, develop algorithms for effective treatment of osteoarthritis aimed at reducing the need for anti-inflammatory therapy is of great importance.

AIM: To evaluate the efficacy and safety of hyaluronic acid for the treatment of osteoarthritis in patients with comorbid pathology.

MATERIALS AND METHODS: 30 patients aged 40 to 65 years with II–III stages of knee osteoarthritis who received treatment with the hyaluronate sodium were examined according to the Kellgren–Lawrence scale. The course of treatment included standard intra-articular injections of Revisk (sterile sodium hyaluronate gel obtained by microbial fermentation) into the knee joints once a week, in a course of 3 injections. During the study non-steroidal anti-inflammatory drugs therapy was allowed at stable standard dosages. The effectiveness of treatment was assessed by changes in the WOMAC index, the Visual Analog scale pain scores for pain on movement, at rest, goniometry data, 30-meters walking test and stair climb test.

RESULTS: A positive effect of treatment on all the parameters has been noted: significant improvement in clinical indicators of pain according to the visual analog scale, functional tests, and the WOMAC index scores. The positive dynamics of the estimated parameters during treatment started from the 7th day of therapy.

CONCLUSIONS: The hyaluronate sodium (Revisk) can be used for treating patients with II–III stages of knee osteoarthritis with moderate dysfunction of joints.

Keywords

osteoarthritis / Revisk / visual analog scale / WOMAC index / quality of life

References

[1] Lila AM, Alekseeva LI, Telyshev КA. Current approaches to osteoarthritis phenotyping. Modern Rheumatology Journal. 2019;13(2):4–8. (In Russ.) DOI: 10.14412/1996-7012-2019-2-4-8

[2] Лила А.М., Алексеева Л.И., Телышев К.А. Современные подходы к фенотипированию остеоартрита // Современная ревматология. 2019. Т. 13, № 2. С. 4–8. DOI: 10.14412/1996-7012-2019-2-4-8

[3] Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Modern Rheumatology Journal. 2019;13(2):9–21. (In Russ.) DOI: 10.14412/1996-7012-2019-2-9-21

[4] Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение // Современная ревматология. 2019. Т. 13, № 2. С. 9–21. DOI: 10.14412/1996-7012-2019-2-9-21

[5] Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001;60(2):91–97. DOI: 10.1136/ard.60.2.91

[6] Peat G., McCarney R., Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care // Ann. Rheum. Dis. 2001. Vol. 60, No. 2. P. 91–97. DOI: 10.1136/ard.60.2.91

[7] Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018;46(1):32–39. (In Russ.) DOI: 10.18786/2072-0505-2018-46-1-32-39

[8] Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России // Альманах клинической медицины. 2018. Т. 46, № 1. С. 32–39. DOI: 10.18786/2072-0505-2018-46-1-32-39

[9] Lila AM, Alekseeva LI, Taskina EA. Modern approaches to osteoarthritis therapy taking into account updated international guidelines. Russian Medical Inquiry. 2019;3(11–2):48–52. (In Russ.)

[10] Лила А.М., Алексеева Л.И., Таскина Е.А. Современные подходы к терапии остеоартрита с учетом обновленных международных рекомендаций // РМЖ. Медицинское обозрение. 2019. Т. 3, № 11–2. С. 48–52.

[11] Alvarez C, Cleveland RJ, Schwartz TA, et al. Comorbid conditions and the transition among states of hip osteoarthritis and symptoms in a community-based study: a multi-state time-to-event model approach. Arthritis Res Ther. 2020;22(1):12. DOI: 10.1186/s13075-020-2101-x

[12] Alvarez C., Cleveland R.J., Schwartz T.A. et al. Comorbid conditions and the transition among states of hip osteoarthritis and symptoms in a community-based study: a multi-state time-to-event model approach // Arthritis Res. Ther. 2020. Vol. 22, No. 1. P. 12. DOI: 10.1186/s13075-020-2101-x

[13] Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021;33(3):529–545. DOI: 10.1007/s40520-020-01762-2

[14] Leyland K.M., Gates L.S., Sanchez-Santos M.T. et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data // Aging Clin. Exp. Res. 2021. Vol. 33, No. 3. P. 529–545. DOI: 10.1007/s40520-020-01762-2

[15] Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. DOI: 10.1016/j.joca.2019.06.011

[16] Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis // Osteoarthritis Cartilage. 2019. Vol. 27, No. 11. P. 1578–1589. DOI: 10.1016/j.joca.2019.06.011

[17] Denisov LN, Tsvetkova ES, Golubev GSh, et al. The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis is applicable in Russian clinical practice: A consensus statement of leading Russian and ESCEO osteoarthritis experts. Rheumatology Science and Practice. 2016;54(6):641–652. (In Russ.) DOI: 10.14412/1995-4484-2016-641-653

[18] Денисов Л.Н., Цветкова Е.С., Голубев Г.Ш. и др. Алгоритм лечения остеоартрита коленного сустава Европейского общества по клиническим и экономическим аспектам остеопороза и остеоартрита (ESCEO) применим в российской клинической практике: совместное заключение ведущих российских специалистов и экспертов ESCEO по остеоартриту // Научно-практическая ревматология. 2016. Т. 54, № 6. С. 641–653. DOI: 10.14412/1995-4484-2016-641-653

[19] Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350. DOI: 10.1016/j.semarthrit.2019.04.008

[20] Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) // Semin. Arthritis Rheum. 2019. Vol. 49, No. 3. P. 337–350. DOI: 10.1016/j.semarthrit.2019.04.008

[21] Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16–24. DOI: 10.1136/annrheumdis-2018-213826

[22] Kloppenburg M., Kroon F.P., Blanco F.J. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis // Ann. Rheum. Dis. 2019. Vol. 78, No. 1. P. 16–24. DOI: 10.1136/annrheumdis-2018-213826

[23] Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162. DOI: 10.1002/acr.24131

[24] Kolasinski S.L., Neogi T., Hochberg M.C. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee // Arthritis Care Res. (Hoboken). 2020. Vol. 72, No. 2. P. 149–162. DOI: 10.1002/acr.24131

[25] Vincent P. Intra-articular hyaluronic acid in knee osteoarthritis: clinical data for a product family (ARTHRUM), with comparative meta-analyses. Curr Ther Res Clin Exp. 2021;95:100637. DOI: 10.1016/j.curtheres.2021.100637

[26] Vincent P. Intra-articular hyaluronic acid in knee osteoarthritis: clinical data for a product family (ARTHRUM), with comparative meta-analyses // Curr. Ther. Res. Clin. Exp. 2021. Vol. 95. P. 100637. DOI: 10.1016/j.curtheres.2021.100637

[27] Maheu E, Bannuru RR, Herrero-Beaumont G, et al. Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review. Semin Arthritis Rheum. 2019;48(4):563–572. DOI: 10.1016/j.semarthrit.2018.06.002

[28] Maheu E., Bannuru R.R., Herrero-Beaumont G. et al. Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review // Semin. Arthritis Rheum. 2019. Vol. 48, No. 4. P. 563–572. DOI: 10.1016/j.semarthrit.2018.06.002

[29] Goueffic Y, Guilluy C, Guerin P, et al. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res. 2006;72:339–348. DOI: 10.1016/j.cardiores.2006.07.017

[30] Goueffic Y., Guilluy C., Guerin P. et al. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation // Cardiovasc Res. 2006. Vol. 72. P. 339–348. DOI: 10.1016/j.cardiores.2006.07.017

[31] Lee CH, Chiang CF, Kuo FC, et al. High-Molecular-Weight Hyaluronic Acid Inhibits IL-1β-Induced Synovial Inflammation and Macrophage Polarization through the GRP78-NF-κB Signaling Pathway. Int J Mol Sci. 2021;22(21):11917. DOI: 10.3390/ijms222111917

[32] Lee C.H., Chiang C.F., Kuo F.C. et al. High-Molecular-Weight Hyaluronic Acid Inhibits IL-1β-Induced Synovial Inflammation and Macrophage Polarization through the GRP78-NF-κB Signaling Pathway // Int. J. Mol. Sci. 2021. Vol. 22, No. 21. P. 11917. DOI: 10.3390/ijms222111917

[33] Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Investig. 2007;117:175–184. DOI: 10.1172/JCI29881

[34] Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization // J. Clin. Investig. 2007. Vol. 117. P. 175–184. DOI: 10.1172/JCI29881

[35] Pelletier JP, Raynauld JP, Abram F, et al. Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative. Arthritis Res Ther. 2018;20(1):40. DOI: 10.1186/s13075-018-1538

[36] Pelletier J.P., Raynauld J.P., Abram F. et al. Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative // Arthritis Res. Ther. 2018. Vol. 20, No. 1. P. 40. DOI: 10.1186/s13075-018-1538

[37] Karateev AE, Pogozheva ЕYu, Amirdzhanova VN, Filatova ЕS. Hyaluronic acid preparations in the treatment of osteoarthritis: is it clear to us? Modern Rheumatology Journal. 2018;12(3):40–52. (In Russ.) DOI: 10.14412/1996-7012-2018-3-40-52

[38] Каратеев А.Е., Погожева Е.Ю., Амирджанова В.Н., Филатова Е.С. Препараты гиалуроновой кислоты в лечении остеоартрита: все ли нам ясно? // Современная ревматология. 2018. Т. 12, № 3. С. 40–52. DOI: 10.14412/1996-7012-2018-3-40-52

[39] Petukhov AI, Kornilov NN, Kulyaba TA. Injectable hyaluronic acid drugs for the treatment of knee osteoarthritis in the context of evidence-based medicine. Rheumatology Science and Practice. 2018;56(2):239–248. (In Russ.) DOI: 10.14412/1995-4484-2018-239-248

[40] Петухов А.И., Корнилов Н.Н., Куляба Т.А. Инъекционные препараты гиалуроновой кислоты для лечения гонартроза с позиций доказательной медицины // Научно-практическая ревматология. 2018. Т. 56, № 2. С. 239–248. DOI: 10.14412/1995-4484-2018-239-248

[41] Gialuronan v artrologii. Kompleksy gialuronovoi kisloty s nizkomolekulyarnymi bioregulyatorami — novaya stranitsa v lechenii sustavnykh patologi. Ed. by V.N. Khabarov. Moscow: Advansed solyushnz; 2014. 208 p. (In Russ.)

[42] Гиалуронан в артрологии. Комплексы гиалуроновой кислоты с низкомолекулярными биорегуляторами — новая страница в лечении суставных патологий / под ред. В.Н. Хабарова. Москва: Адвансед солюшнз, 2014. 208 с.

[43] Campo GM, Avenoso A, Nastasi G, et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta. 2011;1812(9):1170–1181. DOI: 10.1016/j.bbadis.2011.06.006

[44] Campo G.M., Avenoso A., Nastasi G. et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression // Biochim. Biophys. Acta. 2011. Vol. 1812, No. 9. P. 1170–1181. DOI: 10.1016/j.bbadis.2011.06.006

[45] Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD00532. DOI: 10.1002/14651858

[46] Bellamy N., Campbell J., Robinson V. et al. Viscosupplementation for the treatment of osteoarthritis of the knee // Cochrane Database Syst. Rev. 2006. No. 2. P. CD00532. DOI: 10.1002/14651858

[47] Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. DOI: 10.1186/s12891-015-0775-z

[48] Altman R.D., Manjoo A., Fierlinger A. et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review // BMC Musculoskelet. Disord. 2015. Vol. 16. P. 321. DOI: 10.1186/s12891-015-0775-z

[49] Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. 2012;26(4):257–268. DOI: 10.2165/11632580-000000000-00000

[50] Colen S., van den Bekerom M.P., Mulier M., Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products // BioDrugs. 2012. Vol. 26, No. 4. P. 257–268. DOI: 10.2165/11632580-000000000-00000

[51] Campbell KA, Erickson BJ, Saltzman BM, et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy. 2015;31(10):2036–2045.e14. DOI: 10.1016/j.arthro. 2015.03.030

[52] Campbell K.A., Erickson B.J., Saltzman B.M. et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses // Arthroscopy. 2015. Vol. 31, No. 10. P. 2036–2045.e14. DOI: 10.1016/j.arthro. 2015.03.030

[53] Pasquali Ronchetti I, Guerra D,Taparelli F, et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology (Oxford). 2001;40(2):158–169. DOI: 10.1093/rheumatology/40.2.158

[54] Pasquali Ronchetti I., Guerra D.,Taparelli F. et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis // Rheumatology (Oxford). 2001. Vol. 40, No. 2. P. 158–169. DOI: 10.1093/rheumatology/40.2.158

[55] Revmatologiya. Klinicheskie rekomendatsii. Ed. by E.L. Nasonov. 2nd ed. Moscow: GEOTAR-Media; 2010. (In Russ.)

[56] Ревматология. Клинические рекомендации / под ред. Е.Л. Насонова. 2-е изд. Москва: ГЕОТАР-Медиа, 2010.

RIGHTS & PERMISSIONS

Eco-Vector